6 results
The hypothesis is that the amivantamab and lazertinib combination (Arm A) will demonstrate superior PFS compared with single-agent osimertinib (Arm B).
The objective of this study is to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with symptomaticheart failure with reduced ejection fraction (HFrEF).
This is a pilot study to assess the feasibility and tolerability of mitochondrial oxygenation measurements in patients with moderate to severe claudication (Rutherford class 4-6) with the COMET device in combination with Alacare. As secondary aims…
The purpose of this study is to assess the efficacy of adding lazertinib to amivantamab, carboplatin, and pemetrexed (LACP/ACP-L dosing strategies) and amivantamab, carboplatin and pemetrexed (ACP) compared with carboplatin and pemetrexed (CP) in…
The aim of this prospective single-arm phase II study is to evaluate the efficacy of amivantamab and bevacizumab added to continued treatment with a third-generation EGFRTKI (osimertinib or lazertinib), for patients with EGFR-mutant advanced NSCLC,…
1. To describe mitoPO2 in clinically admitted critically ill septic patients receiving fluid therapy (consisting of crystalloid, albumin and/or red cell transfusion).2. To describe the effects of fluid therapy on mitoPO2 and on other physiological…